메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

라이프

Lunit AI Maps the Tumor-Immune Landscape to Predict Immunotherapy Response and Discover New Antibody Targets at SITC 2025

Studies reveal how the Lunit SCOPE® suite identifies immunotherapy-responsive subtypes, standardizes immune phenotyping, and accelerates antibody-based target discovery SEOUL, South Korea, Nov. 7, 2025 -- Lunit (KRX:328130), a leading provider of AI for cancer diagnostics and precision oncology, today announced the presentation of three studies at the Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting, taking place November 5-9 in Maryland, U.S. The findings highlight how Lunit's AI-powered digital pathology technologies—Lunit SCOPE IO® and Lunit SCOPE®
- 김갑성 기자
- 2025-11-07 22:05
HanchorBio Presents Two Late-Breaking Abstracts at the Society for Immunotherapy of Cancer 2025 Demonstrating Best-in-Class Potential of HCB101 in Advanced Cancers

[ 메디채널 김갑성 기자 ] Late-breaking poster presentations show HCB101's favorable safety, strong receptor occupancy, and promising monotherapy and combination activity in tumors historically unresponsive to immunotherapy TAIPEI, SHANGHAI, and SAN FRANCISCO, Nov. 7, 2025 -- HanchorBio Inc. (TPEx: 7827), a global clinical-stage biotechnology company advancing next-generation immunotherapies for oncology and autoimmune diseases, today announced the presentation of two late-breaking abstracts on its lead asset, HCB101, at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
- 김갑성 기자
- 2025-11-07 22:00
2025 Aurora Prize for Awakening Humanity Awarded to Dr. Jamal Eltaeb

Head of Al Nao Hospital in Sudan recognized for sustaining critical medical care amid civil warand saving hundreds of lives NEW YORK, Nov. 7, 2025 -- The Aurora Humanitarian Initiative announced Thursday evening that Dr. Jamal Eltaeb has been named the 2025 Aurora Prize Laureate. The $1 million Aurora Prize for Awakening Humanity honors individuals who risk their lives to save others. This year, Aurora recognizes Dr. Eltaeb's extraordinary courage and steadfast dedication to providing care for those trapped in conflict. Amid Sudan's devastating civil war and the
- 김갑성 기자
- 2025-11-07 21:59
Brii Biosciences Announces Publication of Phase 2 ENSURE Study Results in Nature Medicine

Findings provide scientific insights into the contribution of small interfering RNA (siRNA) and therapeutic vaccination towards the HBV functional cure strategy DURHAM, N.C. and BEIJING, Nov. 7, 2025 -- Brii Biosciences Limited ("Brii Bio," or the "Company," stock code: 2137.HK), a biotechnology company developing therapies to improve patient health across diseases with high unmet medical need, today announced the publication of results from its Phase 2 ENSURE study in the peer-reviewed journal Nature Medicine. The study evaluates the efficacy and safet
- 김갑성 기자
- 2025-11-07 21:30
EBR Systems Achieves First Enrollments in the WiSE-UP Study for Heart Failure Patients

The WiSE-UP post-approval study is gathering real-world evidence from commercially treated patients using the WiSE® left ventricular endocardial pacing (LVEP) system. Key Highlights: The first two patients have now been enrolled in the WiSE-UP post-approval study by Dr Devi Nair from St Bernards Heart & Vascular Center, Arkansas The EBR-sponsored study will evaluate real-world outcomes for heart failure patients receiving the FDA-approved WiSE® System for delivering LVEP in patients unable to receive traditional cardiac resynchronization therapy (CRT) T
- 김갑성 기자
- 2025-11-07 21:00
Coreline Soft Unveils AVIEW 2.0 at RSNA 2025: Next-Generation AI Platform Redefining Radiology Workflow Standards

CHICAGO and SEOUL, South Korea, Nov. 7, 2025 -- Coreline Soft will introduce its groundbreaking chest AI platform AVIEW 2.0 at RSNA 2025 (November 30–December 4, Chicago), demonstrating how unified AI automation is fundamentally transforming radiology workflows and elevating diagnostic precision across pulmonary, cardiac, and airway pathologies. AVIEW 2.0 represents a paradigm shift from task-specific tools to an integrated diagnostic ecosystem. The platform seamlessly combines lung-cancer screening (LCS), coronary-artery calcium scoring (CAC), and COPD quantifica
- 김갑성 기자
- 2025-11-07 21:00
'Coffee Diplomacy' at APEC: Korea-U.S. Startup Imunika Goes Viral as Japan's Motegi Prepares Tariff Talks with Trump

Japan's newly appointed Foreign Minister Toshimitsu Motegi sparked an unexpected viral moment at APEC 2025 after stopping by Imunika — the official coffee sponsor of APEC 2025 Korea, a Korea–U.S. startup redefining "Wellness Specialty Coffee." SEOUL, South Korea and WASHINGTON, Nov. 7, 2025 -- A quiet exchange at the APEC 2025 Korea Summit became one of the event's most unexpected stories. Toshimitsu Motegi, Japan's newly appointed Foreign Minister — soon to help steer Japan–U.S. tariff negotiations — was filmed sampling Imunika, a small bio-fermented coffee startup that unex
- 김갑성 기자
- 2025-11-07 21:00
Pigeon Showcases Parenting Innovations Under "The Nest" Theme at CIIE 2025

SHANGHAI, Nov. 7, 2025 -- During the 8th China International Import Expo (CIIE) at the National Exhibition and Convention Center, Pigeon unveiled its latest advances in feeding and baby care science under the theme "The Nest". 23 Years in China: Pigeon Expands from Local Innovation to Global Leadership Within the CIIE Consumer Goods exhibition area (Hall 6.1), Pigeon's baby feeding bottles have become a signature highlight. As the trusted global leader in high-quality, precision-engineered baby and maternity care products, Pigeon celebrates 23 years in C
- 김갑성 기자
- 2025-11-07 20:20
Alebund Presents Phase 3 Trial Results of AP301 at the American Society of Nephrology (ASN) 2025 Congress

[ 메디채널 김갑성 기자 ] Clinically and statistically significant superiority of AP301 maintenance dose versus ineffective low dose in reducing serum phosphate levels was established and AP301's efficacy is sustained throughout the 52 weeks of treatment. The non-inferiority of AP301 to sevelamer carbonate in reducing serum phosphate levels was demonstrated. Overall, AP301 was safe and well-tolerated. The most common AEs were discolored feces and diarrhea. Diarrhea generally occurred early and resolved without treatment changes. No evidence of iron accumulation was observed with cumulative AP301
- 김갑성 기자
- 2025-11-07 20:00
Smartee Celebrates the Opening of its 4.0 Digital Orthodontic Technology Exhibition Hall in Jiaxing, China

JIAXING, China, Nov. 7, 2025 -- Smartee Denti-Technology has unveiled the Smartee Digital Orthodontic Technology Exhibition Hall, a 1,200-square-meter space dedicated to showcasing the company's innovations in clear aligner therapy and digital orthodontics. The event gathered a distinguished group of domestic orthodontic professionals, including Prof. Gang Shen and his orthodontic team, Ms. Paula Fabbie, Certified Orofacial Myologist and Examiner from IAOM (International Association of Orofacial Myology), Prof. Zhen Shi, Prof. Xue Feng, and Dr. Lei Shu, along with 21 orthodontists from
- 김갑성 기자
- 2025-11-07 18:05

이전

51 52 53 54 55 56 57 58 59 60

많이 본 기사

최근기사

2026-01-01_THU

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2026년 01월 01일 22시 40분